EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast To 2023
(PRWEB) July 16, 2014
Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a persons symptoms, changes in the ST-tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survioc: val probabilities.
The epidemiology of ACS in the 7MM has changed significantly during the past two decades and varies between the western and Japanese markets. In order to capture the country-specific trends and provide detailed patient population segmentation, GlobalData epidemiologists built separate forecasts for (myocardial infarction) (MI) and UA in the 7MM and used a case-flow methodology to determine the number of cases that survived until hospital discharge and for one year after hospital discharge.
- The ACS EpiCast Report provides an overview of the ACS risk factors and comorbidities, a discussion of the ACS global and historical trends, and a 10-year epidemiological patient forecast for ACS from 2013 to 2023 in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan)
- Hospitalized incident cases of ACS, segmented by STEMI, NSTEMI, and UA
- ACS cases that survived until hospital discharge, segmented by STEMI, NSTEMI, and UA
- ACS cases that survived for one year post-hospital discharge, segmented by STEMI, NSTEMI, and UA
- Diagnosed prevalent cases of myocardial infarction (MI) segmented by STEMI and NSTEMI from 2013 to 2023 in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK)
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global ACS market.
- Quantify patient populations in the global ACS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the patient segmentations that present the best opportunities for ACS therapeutics in each of the markets covered.
- Identify the number of ACS cases survived to key time periods.
To Inquire Before Buying Report: http://www.marketresearchreports.biz/analysis/211840
Table of Content
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.2.1 Controlling hypertension can decrease the CHD incidence by 20-25%
3.2.2 Every 1% decrease in cholesterol levels is associated with a 2% decrease in the CHD risk
3.2.3 Women who have diabetes have a higher risk of developing CHD than men with diabetes
3.2.4 Cigarette smoking increases the risk of CHD and also increases the risk of developing other risk factors for CHD
To Download Full Report With TOC: http://www.marketresearchreports.biz/sample/sample/211840
MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries. Kindly visit: http://www.marketresearchreports.biz/.